Biblio

Export 81 results:
Author [ Keyword(Desc)] Title Type Year
Filters: Author is Vellas, Bruno  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Aged
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb, A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis., J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb, Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease., J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
A. Jacquin-Piques, Sacco, G., Tavassoli, N., Rouaud, O., Bejot, Y., Giroud, M., Robert, P., Vellas, B., and Bonin-Guillaume, S., Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home., J Alzheimers Dis, vol. 49, no. 3, pp. 671-80, 2016.
C. Reed, Happich, M., Argimon, J. Maria, Haro, J. Maria, Wimo, A., Bruno, G., Dodel, R., Jones, R. W., Vellas, B., and Belger, M., What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study., J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
Alzheimer Disease
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb, A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis., J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb, Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease., J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria., Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
C. Reed, Happich, M., Argimon, J. Maria, Haro, J. Maria, Wimo, A., Bruno, G., Dodel, R., Jones, R. W., Vellas, B., and Belger, M., What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study., J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.

Pages